Annika Margareta Grahn-Westin

Visionar Preclinical AB is a CRO specialized on in vivo preclinical contract research and services. The company was founded year 2000 by individuals with extensive experience of preclinical research and development in international pharmaceutical companies. Its customers are small and mid-size companies who work with drugs, biopharmaceuticals, or medical devices. Quality and flexibility are key factors in their work. Its extensive experience makes it possible for them to find unconventional solutions to preclinical matters. It work closely with their Sponsors to develop strategies for cost effective evaluation of drug candidates and to perform necessary regulatory studies for phase I-II clinical trials.

Visionar Preclinical AB is a CRO specialized on in vivo preclinical contract research and services. The company was founded year 2000 by individuals with extensive experience of preclinical research and development in international pharmaceutical companies. Its customers are small and mid-size companies who work with drugs, biopharmaceuticals, or medical devices. Quality and flexibility are key factors in their work. Its extensive experience makes it possible for them to find unconventional solutions to preclinical matters. It work closely with their Sponsors to develop strategies for cost effective evaluation of drug candidates and to perform necessary regulatory studies for phase I-II clinical trials.

Visionar Preclinical AB is a CRO specialized on in vivo preclinical contract research and services. The company was founded year 2000 by individuals with extensive experience of preclinical research and development in international pharmaceutical companies. Its customers are small and mid-size companies who work with drugs, biopharmaceuticals, or medical devices. Quality and flexibility are key factors in their work. Its extensive experience makes it possible for them to find unconventional solutions to preclinical matters. It work closely with their Sponsors to develop strategies for cost effective evaluation of drug candidates and to perform necessary regulatory studies for phase I-II clinical trials.